NeuShen Announces Upcoming Participation at Conferences
- East-West Biopharma Summit Road Trip: New York--Boston--San Diego--Silicon Valley, Oct 20, Boston, US
- Bio-Europe 2022, Oct. 24-26, Leipzig, DE
- BioCentury- BayHelix East-West Biopharma Summit, Nov. 14-18, San Francisco, US
SHANGHAI, China, and Boston, MA--NeuShen Therapeutics, Inc., a biotechnology company focusing on developing innovative treatments for central nervous system (CNS) disorders with dual platforms of AAV-based gene therapy and small molecule discovery, announced today the participation of following conferences:
East-West Biopharma Summit Road Trip: New York--Boston--San Diego--Silicon Valley, Oct 20, Boston, USDr. Joan Shen, Founder and CEO
Panelist: Biotech Company's Opportunity during this Winter
Bio-Europe 2022, Oct. 24-26, Leipzig, DEDr. Joan Shen, Founder and CEO
One on one group meeting open to schedule for discussing potential collaboration and financing.
BioCentury- BayHelix East-West Biopharma Summit, Nov. 14-18, San Francisco, USDr. Joan Shen, Founder and CEO
Present on Strategy Workshop: Planting Footprints Abroad on Wednesday, Nov 16.
About NeuShen Therapeutics
NeuShen Therapeutics is a biotechnology company focusing on innovative drug research and development to address CNS disorders, applying dual research platforms, including AAV-based gene therapy and small molecule discovery. With operations both in Shanghai, China and Boston, MA, NeuShen has a world-class team and is honored to be advised by an outstanding Board of Directors and Scientific Advisory Board.
Related News
